东莞粤港澳干细胞生物科技有限公司，实缴注册资金1亿元，是一家专注于细胞储存、生物技术研发及细胞相关临床前研究的科技服务型企业。公司与国家干细胞转化资源库签约共建东莞细胞资源库，共同推进干细胞储存技术和IPSC研发创新。公司于2022年11月获聘为中国干细胞产业联盟首届理事单位，致力带动生命科学与卫生医疗产业的健康发展。
粤港澳生物科技公司主要投资人为广东名店集团、银帝集团以及杰出海归科学家。广东名店集团投资范围涉及生命科学、高新科技、大型商业地产开发、金融投资等领域。集团创始人陈路为清华大学五道口金融学院全球金融GFD博士，曾任东莞市十五届人大常委、东莞市工商联副主席、东莞市青联副主席、广东省浙江商会执行会长、东莞市浙江商会终身荣誉会长、广东名店实业集团有限公司董事长。银帝集团，企业注册资金39亿元，集团总部位于北京CBD核心区。粤港澳生物科技公司拥有雄厚的资金实力和强大的科研力量，重视研发投入和技术创新，强化科研技术攻关。公司创立了恩联干细胞生物科技研究院、清实生物科技有限公司等多家公司，促进干细胞全产业链精准对接和深度融合。
粤港澳生物科技公司高度重视科技创新和人才培养，2023年7月成为广东医科大学附属医院博士后工作站企业联合培养基地，发挥高端人才“蓄水池”效应，致力于促进优秀科研成果孵化和产出。除此之外，公司网罗科研优势创新力量，加强内外联动，先后与中国科学院深圳先进技术研究院、同济大学生命科学与技术学院、香港大学李嘉诚医学院、上海市东方医院、广州医科大学附属第一医院以及上市公司香港医思医疗集团等多家具备学术、科研优势的研究机构和企业形成“产，学、研、医”一体化的深度合作模式，搭建互利共赢新平台形成资源共享新格局，共同致力发展大健康与生物医疗事业为“健康中国”护航，造福广大民众。
Dongguan GHM Stem Cell Biotechnology Co., Ltd., with a paid-in registered capital of 100 million yuan, is a technology service enterprise specializing in cell storage, biotechnological research and development, and preclinical studies related to cells. The company has signed an agreement with the National Stem Cell Translational Resource Bank to jointly establish the Dongguan Cell Resource Bank and collaboratively promote innovations in stem cell storage technology and induced pluripotent stem cell (iPSC) research and development. In November 2022, the company was appointed as a founding council member of the China Stem Cell Industry Alliance, committing to driving the healthy development of the life sciences and healthcare industry.
The main investors of Dongguan GHM Stem Cell Biotechnology Co., Ltd. include GuangDong Mingdian Industrial Group Co., Ltd., and outstanding overseas returnee scientists.GuangDong Mingdian Industrial Group Co., Ltd.'s investment portfolio covers life sciences, high-tech, large-scale commercial real estate development, and financial investments. Chen Lu, the founder of the group, holds a PhD in Global Finance (GFD) from Tsinghua University's PBC School of Finance and has served as a member of the 15th Dongguan Municipal People's Congress Standing Committee, Vice Chairman of the Dongguan Federation of Industry and Commerce, Vice Chairman of the Dongguan Youth Federation, Executive President of the Zhejiang Chamber of Commerce in Guangdong, Lifetime Honorary President of the Zhejiang Chamber of Commerce in Dongguan, and Chairman of Guangdong Famous Stores Industrial Group Co., Ltd. Yindi Group, with a registered capital of 3.9 billion yuan, has its headquarters located in the core area of Beijing's CBD. Dongguan GHM Stem Cell Biotechnology Co., Ltd. boasts strong financial resources and robust research capabilities, emphasizing R&D investment and technological innovation to enhance scientific research breakthroughs. The company has founded multiple subsidiaries, including Enlife Stem Cell Biotechnology Research Institute and Chayshire Biotechnology Co., Ltd., to facilitate precise connections and deep integration across the entire stem cell industry chain.
The company attaches great importance to technological innovation and talent cultivation. In July 2023, it became a joint training base for the postdoctoral workstation of the Affiliated Hospital of Guangdong Medical University, serving as a "talent pool" to promote the incubation and output of excellent scientific research achievements. In addition, the company leverages its research advantages and innovative strengths, strengthens internal and external collaboration, and has established a deep "industry-academia-research-medicine" integrated cooperation model with several research institutions and enterprises with academic and research advantages, including the Shenzhen Institutes of Advanced Technology of the Chinese Academy of Sciences, the School of Life Sciences and Technology of Tongji University, the Li Ka Shing Faculty of Medicine of the University of Hong Kong, Shanghai East Hospital, the First Affiliated Hospital of Guangzhou Medical University, and the listed company EC Healthcare Group. This cooperation aims to build a new platform for mutual benefit and win-win cooperation, form a new pattern of resource sharing, and jointly contribute to the development of the health and biomedical industry, safeguarding "Healthy China" and benefiting the general public.